Humalog
(insulin lispro)ApprovedSmall molecule
Eli LillyInsulin lispro is used to help people with diabetes control their blood sugar levels by replacing the insulin their body cannot make or use properly. It works quickly to lower blood sugar after meals.[2] Humalog is currently approved and in use across 14 indications[4].[1]
Humalog is one of 333 small molecule programs targeting Gestational Diabetes. It is currently in Approved.
14
Indications
122
Total Trials
4
Active Trials
332
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 13 indications
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Humalog
Eli LillyApproved
Singulair
AstraZenecaPreclinical
Nucala
GGlaxo Dba Glaxosmithkline
Preclinical
Spiriva
Boehringer IngelheimPreclinical
Qvar
Chiesi Farmaceutici S.p.A.Preclinical
Symbicort
AstraZenecaPreclinical
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Ozone
TTanta University
Preclinical
Blood Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Spiriva
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 1 Diabetes Mellitus23 trials
Show 20 more trials
Type 1 Diabetes21 trials
Show 18 more trials
Type 2 Diabetes14 trials
Show 11 more trials
ART13 trials
Show 10 more trials
Type 2 Diabetes Mellitus8 trials
Show 5 more trials
27 more indications
MPA7 trials
Type 2 Diabetic Patients2 trials
Gestational Diabetes2 trials
Safety and Efficacy2 trials
Oxidative Stress1 trial
Hyperglycemia1 trial
Cognition1 trial
Diabetes1 trial
PK/PD Study of Intranasal Insulin in Type I Diabetes
Unknown status·—·Phase 1·NCT01201278·20 enrolled
Clinical Trial1 trial
Comparing Efficacy of Autologous Serum Eye Drops With and Without Insulin in Autoimmune Dry Eye: A Randomized Clinical Trial
Active, not recruiting·IInstituto de Oftalmología Fundación Conde de Valenciana·Phase 3·NCT06931041·25 enrolled
Tics1 trial
Hypertrophy1 trial
Type 1 Diabetic1 trial
Insulin Sensitivity1 trial
Chronic Kidney Disease1 trial
Randomized1 trial
Complication1 trial
Asthma1 trial
Absorption1 trial
Infusion1 trial
Unspecified6 trials
Regulatory
FDA Approval Timeline[5]
Jun 14, 1996
INSULIN LISPRO
BLA BLA020563
Dec 22, 1999
HUMALOG MIX75/25
BLA BLA021017
Dec 22, 1999
HUMALOG MIX50/50 KWIKPEN
BLA BLA021018
May 26, 2015
HUMALOG KWIKPEN
BLA BLA205747
Dec 11, 2017
ADMELOG
BLA BLA209196
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Humalog drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for insulin lispro. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]